Markets:

Overview

News

Currencies

International

Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

2.390 -0.080 (-3.24%)

Streaming Delayed Price Updated: 3:55 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tharimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

March 24, 2025

Via ACCESS Newswire

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

March 04, 2025

Via ACCESS Newswire

Tharimmune to Present at the Microcap Conference 2025

January 27, 2025

Via ACCESS Newswire

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

December 16, 2024

Via ACCESSWIRE

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024 ↗

August 12, 2024

Tharimmune just reported results for the second quarter of 2024.

Via InvestorPlace

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

December 06, 2024

Via ACCESSWIRE

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

November 27, 2024

Via ACCESSWIRE

What's Going On With Tharimmune Shares Monday? ↗

November 18, 2024

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver...

Via Benzinga

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

November 18, 2024

Via ACCESSWIRE

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

November 13, 2024

Via ACCESSWIRE

10 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 04, 2024

Via Benzinga

Tharimmune Announces Upcoming Conference Presentations

November 04, 2024

Via ACCESSWIRE

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast ↗

October 30, 2024

Via Benzinga

S&P 500 Edges Lower; US Crude Oil Inventories Fall ↗

October 30, 2024

Via Benzinga

Topics Stocks

What's Going On With Tharimmune Shares Wednesday? ↗

October 30, 2024

Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

Dow Surges Over 150 Points; Alphabet Posts Upbeat Results ↗

October 30, 2024

Via Benzinga

Topics Stocks

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

October 30, 2024

Via ACCESSWIRE

Tharimmune Announces Upcoming Conference Presentations

October 25, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 30, 2024

Via Benzinga

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

September 30, 2024

Via ACCESSWIRE

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

September 16, 2024

Via ACCESSWIRE

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

July 22, 2024

Via ACCESSWIRE

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

July 17, 2024

Via ACCESSWIRE

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

July 16, 2024

Via ACCESSWIRE

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

July 10, 2024

Via ACCESSWIRE

Tharimmune Announces $2.08 Million Private Placement

June 20, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 17, 2024

Via Benzinga

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 17, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Tharimmune, Inc. - Common Stock (NQ:THAR)

All News about Tharimmune, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today